COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Phase 3 Randomized Double-Blind Placebo-Controlled Study of NRP104 in Children Aged 6-12 With ADHD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00556296
Recruitment Status : Completed
First Posted : November 9, 2007
Last Update Posted : June 21, 2011
Information provided by:
New River Pharmaceuticals

Brief Summary:
This study is designed to assess efficacy and safety of NRP-104 administered as a daily dose of 30mg, 50mg or 70mg compared to placebo in the treatment of children aged 6-12 years with ADHD.

Condition or disease Intervention/treatment Phase
Attention Deficit Hyperactivity Disorder Drug: NRP104 Drug: NRp104 Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 297 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Multi-Center, Double-Blind, Parallel-Group, Placebo-Controlled Study of NRP104 in Children Aged 6-12 Years With Attention Deficit Hyperactivity Disorder
Study Start Date : October 2004
Actual Study Completion Date : September 2005

Arm Intervention/treatment
Experimental: 1 Drug: NRP104
NRP104 30mg capsule once daily in a.m.

Experimental: 2 Drug: NRP104
NRP104 50mg capsule once daily in a.m.

Experimental: 3 Drug: NRp104
NRP104 70mg capsule once daily in a.m.

Placebo Comparator: 4 Drug: Placebo

Primary Outcome Measures :
  1. Change score from baseline of the ADHD-RS [ Time Frame: 4 weeks ]

Secondary Outcome Measures :
  1. Duration of therapeutic responses using the CPRS ADHD Index [ Time Frame: At treatment endpoint, separately for morning, afternoon and evening responses ]
  2. Clinical global impression of severity(CGI-S) and improvement (CGI-I) [ Time Frame: Treatment endpoint ]
  3. Treatment emergent AEs [ Time Frame: 4 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Years to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • primary diagnosis of ADHD combined subtype or the predominantly hyperactive-impulsive subtype based on a psychiatric evaluation that reviews DSM-IV criteria
  • functioning at age appropriate levels intellectually
  • blood pressure measurements within the 95th percentile for their gender, height and age
  • ECG results are within the normal range

Exclusion Criteria:

  • comorbid psychiatric diagnosis (such as psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder) or other symptomatic manifestations
  • history of seizures (exclusive of febrile seizure), a tic disorder, or a family history of Tourette's disorder
  • weighs less than 55 lbs (25 kg)or is significantly overweight or obese
  • clinically significant ECG abnormality
  • documented allergy or intolerance to amphetamines

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00556296

Sponsors and Collaborators
New River Pharmaceuticals
Layout table for investigator information
Study Director: Suma Krishnan New River Pharmaceuticals
Additional Information:
Publications of Results:
Faraone SV, Spencer TJ, Kollins SH and Glatt SJ. Moderators of Dose-Response Effects of Lisdexamfetamine Dimesylate Treatment in Children With ADHD. Journal of ADHD and Related Disorders 1(3):16-24, 2010

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00556296    
Other Study ID Numbers: NRP104.301
First Posted: November 9, 2007    Key Record Dates
Last Update Posted: June 21, 2011
Last Verified: June 2011
Additional relevant MeSH terms:
Layout table for MeSH terms
Attention Deficit Disorder with Hyperactivity
Attention Deficit and Disruptive Behavior Disorders
Neurodevelopmental Disorders
Mental Disorders
Neurologic Manifestations
Nervous System Diseases
Lisdexamfetamine Dimesylate
Central Nervous System Stimulants
Physiological Effects of Drugs
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents